Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
LLY	ELI LILLY & CO	NYSE	Drug Manufacturers - General	$1.03T	$1,085.19	-2.07%	$24.40B	52.96x	3.83	United States
GSK	GSK PLC	NYSE	Drug Manufacturers - General	$101.29B	$50.22	-0.79%	$10.28B	13.92x	2.82	United Kingdom
GRFS	GRIFOLS SA	NASDAQ	Drug Manufacturers - General	$6.52B	$9.49	0.11%	$1.71B	37.07x	2.18	United States
GILD	GILEAD SCIENCES INC	NASDAQ	Drug Manufacturers - General	$149.71B	$120.67	-2.96%	$13.67B	18.54x	1.72	United States
AMGN	AMGEN INC	NASDAQ	Drug Manufacturers - General	$177.76B	$330.11	-3.37%	$16.53B	25.33x	8.37	United States
BMY	BRISTOL MYERS SQUIBB CO	NYSE	Drug Manufacturers - General	$113.80B	$55.90	-1.45%	$12.94B	18.82x	4.22	United States
MRK	MERCK & CO INC	NYSE	Drug Manufacturers - General	$275.48B	$110.99	2.20%	$27.65B	14.66x	1.50	United States
AZN	ASTRAZENECA PLC	NASDAQ	Drug Manufacturers - General	$291.43B	$94.01	-1.21%	$19.64B	30.98x	1.49	United Kingdom
AMRN	AMARIN CORP PLC	NASDAQ	Drug Manufacturers - General	$341.00M	$16.40	16.89%	-$80.28M	-3.90x	0.44	Ireland
OGN	ORGANON & CO	NYSE	Drug Manufacturers - General	$2.11B	$8.13	-0.73%	$1.56B	4.21x	13.96	United States
SNY	SANOFI	NASDAQ	Drug Manufacturers - General	$121.59B	$48.13	-0.50%	$18.05B	11.09x	0.78	France
ABBV	ABBVIE INC	NYSE	Drug Manufacturers - General	$396.12B	$224.13	-3.98%	$12.49B	168.52x	-51.66	United States
JNJ	JOHNSON & JOHNSON	NYSE	Drug Manufacturers - General	$495.71B	$205.75	-0.84%	$39.78B	19.73x	1.43	United States
NVS	NOVARTIS AG	NYSE	Drug Manufacturers - General	$272.45B	$141.46	-0.37%	$28.18B	19.19x	1.41	Switzerland
PFE	PFIZER INC	NYSE	Drug Manufacturers - General	$143.79B	$25.29	0.04%	$15.84B	14.70x	1.25	United States
BIIB	BIOGEN INC	NASDAQ	Drug Manufacturers - General	$27.29B	$186.00	-0.49%	$2.71B	16.92x	0.60	United States
SCLX	SCILEX HOLDING CO	NASDAQ	Drug Manufacturers - General	$100.81M	$13.29	-0.45%	-$319.06M	-0.42x	-2.54	United States
MIRA	MIRA PHARMACEUTICALS INC	NASDAQ	Drug Manufacturers - General	$62.40M	$1.49	0.68%	-$5.60M	-0.57x	0.01	United States
MDCX	MEDICUS PHARMA LTD	NASDAQ	Drug Manufacturers - General	$34.37M	$1.56	-0.64%	-$29.72M	-0.73x	-11.85	United States
NSRX	NASUS PHARMA LTD	NYSEMKT	Drug Manufacturers - General	$63.97M	$7.10	4.72%	N/A	N/A	-1.15	Israel

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jan 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: A.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 56, which is 17 points higher than the general drug manufacturer industry average of 39.

LLY passed 22 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 37.85% over the past year, overperforming other general drug manufacturer stocks by 8 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,120.71, an upside of 3.27% from Eli Lilly & Co's current stock price of $1,085.19.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 17 analysts covering Eli Lilly & Co, 64.71% have issued a Strong Buy rating, 17.65% have issued a Buy, 17.65% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: C, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -3 points lower than the general drug manufacturer industry average of 39. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 48.8% over the past year, overperforming other general drug manufacturer stocks by 19 percentage points.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 38, which is -1 points lower than the general drug manufacturer industry average of 39. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 14 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 24.87% over the past year, underperforming other general drug manufacturer stocks by -5 percentage points.

Grifols Sa has an average 1 year price target of $10.00, an upside of 5.37% from Grifols Sa's current stock price of $9.49.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.6%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.76%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

2. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 4.18%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.76%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

3. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 3.4%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.76%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 99.4% indicates that its dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.73% in the last day, and up 0.89% over the last week. Abbvie was the among the top losers in the drug manufacturers - general industry, dropping -3.98% yesterday.

AbbVie shares are trading lower after the company issued Q4 and FY25 adjusted EPS guidance. Wolfe Research downgraded the stock from Outperform to Peer Perform and a report suggested the company is not in discussions with Revolution Medicines.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -49.19% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -79 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 23.38% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -7 percentage points.

3. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 43, which is 4 points higher than the general drug manufacturer industry average of 39. It passed 3 out of 7 valuation due diligence checks.

Merck & Co's stock has gained 11.16% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -19 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 4.41% over the next year.

42.11% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 26.32% of general drug manufacturer stocks are rated B (Buy), 21.05% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 45.58x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.